Demand Fundamental	Value	Score	Rating
Qtr/Qtr Revenue Growth	Members Only
Qtr/Qtr Earnings Growth	Members Only
Year/Year Revenue Growth	Members Only
Year/Year Earnings Growth	Members Only
Multi-Year Revenue Growth	Members Only
Multi-Year Earnings Growth	Members Only
Relative PE Ranking	Members Only
Return on Equity	Members Only
Yield	Members Only
Institutional Holding	Members Only
Stock Price	Members Only
Relative Fundamental Ranking	Members Only
Total Score	Members Only

Demand Technical	Value	Score	Rating
Recommended Condition	Members Only
Trading Zone	Members Only
Average Trading Volume	Members Only
Industry Bull/Bear Condition	Members Only
Sector Bull/Bear Condition	Members Only
Current Signal Start Date	Members Only
Total Score	Members Only

Bristol-Myers Squibb Company, a global biopharmaceutical company, discovers, develops, and delivers innovative medicines that help patients prevail over serious diseases. The company focuses on areas of serious unmet medical needs, such as cardiovascular disease, mental illness, cancer, HIV/AIDS, hepatitis B and C, rheumatoid arthritis, type 2 diabetes, solid organ transplantation, and Alzheimer's disease. Its principal products include PLAVIX for protection against fatal or non-fatal heart attack or stroke- AVAPRO/AVALIDE for the treatment of hypertension and diabetic nephropathy- ABILIFY, an agent for adult patients with schizophrenia, bipolar mania disorder, and depressive disorder- and REYATAZ for the treatment of HIV. The company's principal products also comprise SUSTIVA for the treatment of HIV- BARACLUDE, an inhibitor of hepatitis B virus- ERBITUX to target and block the epidermal growth factor receptor- SPRYCEL for treatment of chronic myeloid leukemia in adults- IXEMPRA to treat breast cancer- ORENCIA to severe rheumatoid arthritis in adults- and ONGLYZA for the treatment of type 2 diabetes. Its products under Phase III clinical trials include ELIQUIS to prevent and treat venous thromboembolic disorders and stroke prevention in atrial fibrillation- NULOJIX to prevent solid organ transplant rejection- Brivanib to block the VEGF and the FGF receptors- Dapagliflozin to treat diabetes- YERVOY to treat metastatic melanoma- and Necitumumab for anticancer treatment. The company sells its products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, and pharmacies. It has strategic alliances with sanofi-aventis- Pfizer, Inc.- AstraZeneca PLC- Otsuka Pharmaceutical Co., Ltd.- Eli Lilly and Company- and Gilead Sciences, Inc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.